Stelara linked with better outcomes in Crohn’s

Treatment with Stelara was associated with superior outcomes in patients with Crohn’s disease who previously failed anti-TNF therapy, according to study results.Marieke J. Pierik, MD, PhD, from the department of gastroenterology and hepatology at Maastricht University Medical Center, and colleagues sought to compared Stelara (ustekinumab, Janssen) with Entyvio (vedolizumab, Takeda) in a real-life setting.“No head-to-head trials comparing vedolizumab vs. ustekinumab in anti-TNF refractory CD patients are available or planned,” they wrote.Researchers included patients with CDRead More

Share on facebook
Share on twitter
Share on linkedin